Success Story: From Biomedical Disease Research to I-140 EB-1B Approval for a Biomedical Scientist
Client’s Testimonial:
"Thank you so much for all the support in getting the I-140 application approved.”
On March 16th, 2026, we received another EB-1B (Outstanding Professors and Researchers) approval for a Senior Scientist in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Senior Scientist
Country of Origin: India
State of Residence at the Time of Filing: California
Approval Notice Date: March 16th, 2026
Processing Time: 13 months, 23 days
Case Summary:
A biomedical scientist received I-140 EB-1B approval for her work in biomedical science, with a research record focused on immunology, disease pathogenesis, and metabolism. The client, who holds a Ph.D., currently works as a senior scientist developing human genetic therapeutics for rare diseases. North America Immigration Law Group (Chen Immigration Law Associates) presented the case by showing that her work addressed a practical and medically important need, improving scientific understanding of serious diseases such as tuberculosis, HIV-related complications, diabetes, asthma, liver fibrosis, and rare muscular disorders.
The petition emphasized that the client’s work had significance beyond a narrow research specialty. Her studies helped clarify disease mechanisms, immune responses, and therapeutic development pathways, including analytical assay development supporting clinical-stage research for a rare genetic disease. As one recommendation letter explained: “[Client’s] research is thus clearly in the best interest of the nation.” This framing helped show that her work had both scientific importance and practical relevance for future treatment development.
A major strength of the case was the client’s consistent record of advancing biomedical research across multiple disease areas. Her published work on immune responses to tuberculosis, metabolic regulation, asthma-related airway mechanisms, and HIV-related liver fibrosis showed a sustained pattern of identifying biological mechanisms that other researchers could apply, test, and extend. The petition also connected her work to broader U.S. public health priorities, noting evidence of support from major funding sources including the American Heart Association, the National Institutes of Health, and the National Heart, Lung, and Blood Institute.
To show that the client was internationally recognized as outstanding in the field, we documented 8 peer-reviewed scientific articles, 1 Worldwide Protein Data Bank entry, 237 citations, and at least 30 completed peer reviews. Rather than treating these metrics as automatically sufficient, we explained that the citation record reflected independent reliance by researchers in the United States and abroad, while the peer-review record showed that journals trusted the client to evaluate the quality and validity of others’ work.
The petition was also supported by 5 recommendation letters, including letters from independent experts familiar with the client’s work through her publications and field contributions. Together, these letters reinforced the objective evidence and helped demonstrate how her findings had influenced biomedical research and therapeutic development.
This approval reflects the strength of a carefully prepared I-140 EB-1B petition built around original scientific contributions, independent reliance, peer trust, and practical biomedical relevance. We were proud to help secure this result for a biomedical scientist whose work supports disease research and the continued advancement of therapeutic innovation in the United States.